Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Idiopathic Pulmonary Fibrosis Clinical Trials

A listing of Idiopathic Pulmonary Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (21) clinical trials

Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)

This study is an explorative, prospective, randomized, double-blind, placebo controlled investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each patient can participate in each block only once. In the START block ...

Phase

Study of Pharmacodynamics Pharmacokinetics Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Phase

Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies

Pulmonary fibrosis can be associated with Anti-Neutrophil Cytoplasmic Antibody (ANCA) directed against MPO or with anti-MPO associated vasculitis, leading to increased disability and poor prognosis. The pathophysiology of this association remains unclear. Conventional therapies used for the treatment of vasculitis manifestations are often disappointing for the treatment of pulmonary fibrosis. ...

Phase

A Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis

Thirty-six (36) male or postmenopausal/surgically sterilized female subjects with IPF who are eligible, will be randomly enrolled in a 2:1 ratio (KD025 to SOC) to one of two treatment groups. Subjects randomized to Treatment Group 1 will receive KD025 400 mg QD orally for 24 weeks. Subjects randomized to Treatment ...

Phase

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

This is a proof of concept study to evaluate the efficacy, safety and tolerability of ABT in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Phase

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

Systemic sclerosis (SSc) is a chronic multisystem autoimmune connective tissue disease for which the etiology remains unknown. The prevalence for SSc is between 19-75 cases per 100,000 and it is more frequent in women, with a peak occurrence in the 4th or 5th decade of life. Morbidity and Mortality in ...

Phase

Study to Assess Safety Tolerability Pharmacokinetic and Pharmacodynamic Properties of GLPG1690

A multicenter randomized, double-blind, parallel group, placebo-controlled, exploratory phase IIa study in subjects with Idiopathic Pulmonary Fibrosis (IPF) to evaluate safety, tolerability, PK and PD of GLPG1690. Male and female subjects aged 40 years or older will be screened to determine eligibility. The screening period will be up to 4 ...

Phase

Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

This is an open label study in which eligible IPF subjects who are using supplemental oxygen at rest will receive GBT440 orally daily.

Phase

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.

Phase